palm11-PrRP31

palm11-PrRP31 is a lipidized (palmitoylated) analog of the endogenous neuropeptide prolactin-releasing peptide (PrRP), specifically the 31-amino acid form. It acts as a potent dual agonist at GPR10 (prolactin-releasing peptide receptor) and NPFF-R2 receptors, with high affinity for GPR10 (EC50 values reported as low as 39 pM). The drug is designed to enhance central nervous system penetration and stability compared to native PrRP. In preclinical models with functional leptin signaling, palm11-PrRP31 exhibits strong anorexigenic effects—reducing food intake and body weight—and improves glucose metabolism by lowering plasma insulin, free fatty acids, cholesterol, and triglycerides. It also modulates expression of enzymes involved in lipid metabolism and increases insulin receptor substrate expression. In rodent models with disrupted leptin signaling (e.g., fa/fa rats), it does not reduce body weight or improve glucose tolerance but demonstrates neuroprotective effects such as improved synaptogenesis in the hippocampus. These findings suggest its primary indications are obesity and type 2 diabetes mellitus in patients with intact leptin pathways; it may also have potential for neurodegenerative conditions due to its central actions[3][4][6].

Other names

palmitoylated prolactin-releasing peptide 31lipidized PrRP analogpalm 11-PrRP31palm11-PrRP31palm-11-PrRP31